Navigation Links
Multiple Sclerosis: Treatment and Global Market 2014-2019
Date:7/8/2015

DUBLIN, July 01, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3d9g5t/multiple) has announced the addition of the "Multiple Sclerosis: Treatment and Global Market" report to their offering.

This report cover's the latest pharmaceutical global market insights for Multiple Sclerosis (MS) disease treatments and provides market forecasts, trends, pipelines, patent analysis and profiles of major players within the markets.

Report Highlights:

- The report provides the forecast of global market for Multiple Sclerosis (MS) disease treatments and projections of compound annual growth rates (CAGRs) over the next five years from 2014 to 2019.
- This report make available an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, consultant, members of the pharmaceutical, healthcare and biotechnology industries and anyone interested in the MS disease and its future.
- The importance of identifying overall market trends production opportunities, emerging geographic merger and acquisition opportunities, and insights that provides guidance for the sales growth.
- Discussion on market drivers and inhibitors, and the area of unmet clinical need.
- Information on the regulatory environment and impacts of appovals. agencies.
- Determines the current status of the market for disease-modifying multiple sclerosis (MS) drugs, biologics and vaccines, and to assess their growth potential over a five-year period from 2014 through 2019.
- Special focus is placed on how new products and technologies will affect current market leaders in the MS treatment sector.
- Report presents detailed profiles of the MS disease-modifying products on the market around the world and in the U.S.
- Report covers about all products in the Phase I, II and III stages of clinical development of disease-modifying products and some unique treatments for preclinical stage of development of the disease.
- Report presents detailed profiles of major companies focusing on their development, and international aspects affecting these products.
- Company profiles of all major companies in this segment.

Key Topics Covered:

1 Executive Summary

2 Disease: Introduction
2.1 Disease Overview
2.2 Disease Classification & Types
2.3 Etiology
2.4 Pathophysiology
2.5 Prognosis
2.6 Pharmacoeconomic Burden
2.7 Epidemiology (by geography wherever possible)
2.8 Diagnosis
2.9 Treatment and Management (by geography wherever possible)
2.10 Referral Pathway

3 Market Size: Historical and Forecast
3.1 Global Market - Forecast

4 Drivers and Barriers for the Market

5 Unmet Need Analysis
5.1 Product Profiles for the Major Marketed Products
5.1.1 Product Overview
5.1.2 Efficacy
5.1.3 Safety
5.1.4 Clinical Studies
5.1.5 Current Market Size and Future Assessment
5.1.6 SWOT

6 Pipeline Analysis
6.1 Overview
6.2 Overall Pipeline by Phases of Development
6.3 Registration Phase
6.4 Phase III Pipeline
6.5 Phase II/III Pipeline
6.6 Phase II Pipeline
6.7 Phase I/II Pipeline
6.8 Phase I Pipeline
6.9 IND Filed
6.10 Preclinical Phase
6.11 Discovery Pipeline

7 Key Events and Likely Impact on the Future Market

8 Future Competitive Scenario
8.1 Future Players
8.2 Profiles of Future Players

9 Regulatory aspects

10 Patent Evaluation
10.1 Patent length and market exclusivity

11 Major companies and market share

12 Appendix
12.1 Abbreviations
12.2 Research Methodology
12.3 Disclaimer

13 List of Tables

14 List of Figures

For more information visit http://www.researchandmarkets.com/research/3d9g5t/multiple

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Non-Insured Health Benefits Program Approves AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis
2. Clinical Experts Report on How Varian Technology Can Be Used for the Precise, Noninvasive, Simultaneous Treatment of Multiple Metastases in the Brain, Spine, Head & Neck, and Lung
3. Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
4. Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
5. AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
6. People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis
7. DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen
8. DDW Presentation Examines Stretta As A Versatile And Effective GERD Treatment For Multiple Patient Populations
9. Multiple Studies at American Urological Association Annual Meeting Highlight Accuracy, Broad Applicability of GenomeDxs Decipher Test for Prostate Cancer
10. Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
11. CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD ... ultimately, a cure. , The grants are awarded through a competitive application process ... a wide array of backgrounds and expertise in all areas relevant to PD research. ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... ... pain afflicting 8 of 10 Americans at some point in their lives, some of us ... equally vexing condition stems from a variety of causes that can be effectively targeted by ... president of Atlantic Spine Center. , Nestled between your neck and lower back, the ...
Breaking Medicine News(10 mins):